Pitfalls in meta-analyses on adverse events reported from clinical trials

Pharmacoepidemiology and Drug Safety

Volumn 20, Issue 10, 2011, Pages 1014-1020

  Huang, Han Yao ^a   Andrews, Elizabeth ^b   Jones, Judith ^c   Skovron, Mary Lou ^a   Tilson, Hugh ^d  

^a BRISTOL MYERS SQUIBB   (United States)

^b RTI INTERNATIONAL   (United States)

^c The Degge Group Ltd   (United States)

^d IL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATINE KINASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADVERSE DRUG REACTION; BLEEDING; CLINICAL TRIAL (TOPIC); DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; FOLLOW UP; HEALTH CARE POLICY; META ANALYSIS (TOPIC); NOTE; PRIORITY JOURNAL; RHABDOMYOLYSIS; SYSTEMATIC REVIEW (TOPIC);

CLINICAL TRIALS AS TOPIC; DRUG TOXICITY; HUMANS; META-ANALYSIS AS TOPIC; PHARMACEUTICAL PREPARATIONS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH REPORT; TREATMENT OUTCOME;

EID: 80053274373     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.2208     Document Type: Note

References (33)

1. Recovery.gov. Accessed March, 03, 2010.
2. Chou R, Aronson N, Atkins D, et al. AHRQ series paper 4: assessing harms when comparing medical interventions: AHRQ and the effective health-care program. J Clin Epidemiol 2010; 63(5): 502-512.
3. Chou R, Helfand M. Challenges in systematic reviews that assess treatment harms. Ann Inter Med Jun 21 2005; 142(12 Pt 2): 1090-1099.
4. Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses. Lancet Nov 27 1999; 354(9193): 1896-1900.
5. Cochrane handbook for systematic reviews of interventions. Version 5.0.2 (updated Sept 2009). In The Cochrane collaboration group, Higgins JPT, Green S (eds.).
6. Methods Reference Guide for Effectiveness and Comparative Effectiveness Reviews. Version 1.0 [Draft posted Oct. 2007]. Rockville, MD. Available at: .
7. Advances in Inflammation Research; No. 6. In Epidemiology of adverse reactions to nonsteroidal antiinflammatory drugs, Weber J (ed.). Raven Press: New York, 1984.
8. Hartnell NR, Wilson JP. Replication of the Weber effect using postmarketing adverse event reports voluntarily submitted to the United States Food and Drug Administration. Pharmacotherapy Jun 2004; 24(6): 743-749.
9. Hartnell NR, Wilson JP, Patel NC, Crismon ML. Adverse event reporting with selective serotonin-reuptake inhibitors. Ann Pharmacother Oct 2003; 37(10): 1387-1391.
10. McAdams M, Staffa J, Dal Pan G. Estimating the extent of reporting to FDA: a case study of statin-associated rhabdomyolysis. Pharmacoepidemiol Drug Saf Mar 2008; 17(3): 229-239.
11. Wacholder S, Dosemeci M, Lubin JH. Blind assignment of exposure does not always prevent differential misclassification. Am J Epidemiol Aug 15 1991; 134(4): 433-437.
12. Jurek AM, Greenland S, Maldonado G. How far from non-differential does exposure or disease misclassification have to be to bias measures of association away from the null? Int J Epidemiol Apr 2008; 37(2): 382-385.
13. Segal JB, McNamara RL, Miller MR, et al. Prevention of thromboembolism in atrial fibrillation. A meta-analysis of trials of anticoagulants and antiplatelet drugs. J Gen Intern Med Jan 2000; 15(1): 56-67.
14. Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Inter Med Oct 5 1999; 131(7): 492-501.
15. van Walraven C, Hart RG, Singer DE, et al. Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis. JAMA Nov 20 2002; 288(19): 2441-2448.
16. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA Aug 22-29 2001; 286(8): 954-959.
17. Reicin AS, Shapiro D, Sperling RS, Barr E, Yu Q. Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs (ibuprofen, diclofenac, and nabumetone). Am J Cardiol Jan 15 2002; 89(2): 204-209.
18. Mahaffey KW, Harrington RA, Akkerhuis M, et al. Disagreements between central clinical events committee and site investigator assessments of myocardial infarction endpoints in an international clinical trial: review of the PURSUIT study. Curr Control Trials Cardiovasc Med Jul 17 2001; 2(4): 187-194.
19. Food and Drug Administration UDoHaHS. Guidance for clinical investigators, sponsors, and IRBs adverse event reporting to IRBs improving human subject protection. 2009.
20. Ethgen M, Boutron I, Steg PG, Roy C, Ravaud P. Reporting of harm in randomized controlled trials evaluating stents for percutaneous coronary intervention. Trials 2009; 10: 29.
21. Kashani A, Phillips CO, Foody JM, et al. Risks associated with statin therapy: a systematic overview of randomized clinical trials. Circulation Dec 19 2006; 114(25): 2788-2797.
22. Hopewell S, Wolfenden L, Clarke M. Reporting of adverse events in systematic reviews can be improved: survey results. J Clin Epidemiol Jun 2008; 61(6): 597-602.
23. Sweeting MJ, Sutton AJ, Lambert PC. What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. Stat Med May 15 2004; 23(9): 1351-1375.
24. Tian L, Cai T, Pfeffer MA, Piankov N, Cremieux PY, Wei LJ. Exact and efficient inference procedure for meta-analysis and its application to the analysis of independent 2 x 2 tables with all available data but without artificial continuity correction. Biostatistics (Oxford, England) Apr 2009; 10(2): 275-281.
25. Bradburn MJ, Deeks JJ, Berlin JA, Russell Localio A. Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events. Stat Med Jan 15 2007; 26(1): 53-77.
26. MacDonald TM, Morant SV, Robinson GC, et al. Association of upper gastrointestinal toxicity of non-steroidal anti-inflammatory drugs with continued exposure: cohort study. BMJ Clinical Research Ed Nov 22 1997; 315(7119): 1333-1337.
27. Crowe BJ, Xia HA, Berlin JA, et al. Recommendations for safety planning, data collection, evaluation and reporting during drug, biologic and vaccine development: a report of the safety planning, evaluation, and reporting team. Clinical Trials 2009; 6(5):430-440.
28. Food and Drug Administration. Guidance for Industry: Diabetes mellitus - Evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. Silver Spring, MD, 2008.
29. Ioannidis JP, Evans SJ, Gotzsche PC, et al. Better reporting of harms in randomized trials: an extension of the CONSORT statement. Ann Inter Med Nov 16 2004; 141(10): 781-788.
30. Liberati A, Altman D, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: Explanation and elaboration. Ann Inter Med 2009; 151(4): W1-W29.
31. Mussen F, Salek S, Walker S. A quantitative approach to benefit-risk assessment of medicines--part 1: the development of a new model using multi-criteria decision analysis; part 2: the practical application of a new model. Pharmacoepidemiol Drug Saf Jul 2007; 16(Suppl 1): S42-S46.
32. Forum on Drug Discovery D, and Translation, Board on Health Sciences Policy. Understanding the Benefits and Risks of Pharmaceuticals. Workshop Summary. Institute of Medicine of the National Academies: Washington, DC, 2007.
33. Felli JC, Noel RA, Cavazzoni PA. A multiattribute model for evaluating the benefit-risk profiles of treatment alternatives. Med Decis Making Jan-Feb 2009; 29(1): 104-115.